Stock DNA
Pharmaceuticals & Biotechnology
SEK 71 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.41
-7.26%
1.96
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Mar 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.81%
0%
-23.81%
6 Months
-37.2%
0%
-37.2%
1 Year
-48.6%
0%
-48.6%
2 Years
-54.57%
0%
-54.57%
3 Years
-63.13%
0%
-63.13%
4 Years
-81.78%
0%
-81.78%
5 Years
-89.3%
0%
-89.3%
Redsense Medical AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.77%
EBIT Growth (5y)
14.55%
EBIT to Interest (avg)
-6.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.84
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.62%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.00
EV to EBIT
-57.50
EV to EBITDA
57.50
EV to Capital Employed
2.68
EV to Sales
2.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.23%
ROE (Latest)
-7.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
4.80
12.70
-62.20%
Operating Profit (PBDIT) excl Other Income
-1.20
3.80
-131.58%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.20
5.60
-157.14%
Operating Profit Margin (Excl OI)
-250.00%
300.10%
-55.01%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -62.20% vs 154.00% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -157.14% vs 269.70% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
28.20
25.00
12.80%
Operating Profit (PBDIT) excl Other Income
-1.70
-4.40
61.36%
Interest
0.00
0.00
Exceptional Items
0.00
2.00
-100.00%
Consolidate Net Profit
0.30
-4.50
106.67%
Operating Profit Margin (Excl OI)
-62.30%
-178.10%
11.58%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 12.80% vs 74.83% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 106.67% vs 48.86% in Dec 2023
About Redsense Medical AB 
Redsense Medical AB
Pharmaceuticals & Biotechnology
Redsense Medical AB (publ) is a Sweden-based company, which is primarily involved in the healthcare industry. The Company is active within the field of hemodialysis. It operates as a manufacturer of blood loss detection device that is designed to alarm on blood leakage from the venous blood access. The Company's Redsense system consists of an alarm unit, an extension fiber and a non invasive sensor patch. When the sensor patch is placed over the blood access, it detects any blood coming in contact with the sensor. This can occur if the needle is accidentally dislodged or if blood is leaking during dialysis. The Redsense system is designed to alarm when blood reaches the sensor, so the dialysis caregiver or observing person at home, can apply appropriate action when a venous needle dislodges.
Company Coordinates 
Company Details
Gyllenhammarsvag 26 , HALMSTAD None : 302 92
Registrar Details






